Platelet Reactivity and MES During CEA

NCT ID: NCT01547039

Last Updated: 2012-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to analyze the association between aspirin efficacy and general platelet reactivity in relation to microembolic signals (MES) during carotid endarterectomy (CEA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Artery Stenosis Ischemic Stroke Myocardial Infarction Aspirin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carotid endarterectomy (CEA)

Patients undergoing carotid endarterectomy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Al patients undergoing elective carotid endarterectomy

Exclusion Criteria

* Patients requiring a blood transfusion prior to surgery
* Patients with an inappropriate temporal bone window for transcranial Doppler (TCD)
* Patients on vitamin K antagonists or antiplatelet treatment other then aspirin
* Patients with an artificial cardiac valve
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UMC Utrecht

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gert Jan de Borst

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gert Jan de Borst, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UMC Utrecht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UMC Utrecht

Utrecht, Utrecht, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gert Jan de Borst, MD, PhD

Role: primary

0031887556965

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL33061.051.10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Recurrent Carotid Stenosis
NCT00000527 COMPLETED PHASE2